First Tracks Biotherapeutics
TRAX
30.59
-0.80
-2.55%
First Tracks Biotherapeutics
US · TRAX
#3189 by market cap
Listed 2026
30.59
-0.80
-2.55%
Live - 5344 symbols - heartbeat 41s ago
· 2026-10-08 09:18
Pre-market
33.05
+8.04%
After-hours
29.99
-1.96%
Overnight
31.57
+3.20%
- Market cap
- 1.09B
- P/E (TTM)i
- -6.75
- P/Bi
- 6.48
- EPSi
- -4.92
- Div yieldi
- 0.00%
- 52W posi
- 45%
Reader sentiment
Are you bullish or bearish on TRAX?
Anonymous reader poll. Unscientific, not investment advice.
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.
- CEO
- Mr. Daniel R. Faga
- Employees
- 104
- Headquarters
- San Diego, California, United States of America
- Fiscal year end
- 12-31
Company profile
- Exchange
- US
- Symbol
- TRAX
- Market-cap rank
- #3189
- Listing date
- 2026-04-06
- Market cap
- 1.09B
- Float cap
- 1.06B
- Shares out
- 35.73M
- Float shares
- 34.75M
Sectors & themes
Biotechnology
IPOs
Quote time 2026-10-08 09:18:58 · For reference only, not investment advice and not tailored to your situation.